Skip to content

Exploring the Efficacy of P Grace: A Promising Intervention for Managing Benign Prostatic Hyperplasia (BPH) - An Open-Label, Single-Centric Clinical Study

An open-label, single-centric, Interventional clinical study to assess the effectiveness of P Grace in the Management of Benign Prostatic Hyperplasia (BPH). - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060343
Enrollment
120
Registered
2023-11-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: P grace (Pumpkin seed oil 320 mg) capsules: 1 capsule twice daily along with food morning and evening for 3 months. Control Intervention1: NA: NA

Sponsors

Nutra Grace
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Aged 45 years and above male subjects. Subjects must have low to moderate BPH symptoms. Subjects having symptoms such as delay in initiating micturition, hesitancy, weak urinary stream, straining to void, sensation of incomplete emptying and terminal dribbling. Subjects with increased residual urine volume. USG prostate volume not more than 80 cc. Nocturia, Urgency, bladder pain, dysuria. Willingness to sign the informed consent, follow the protocol, and participate in clinical trials voluntarily.

Exclusion criteria

Exclusion criteria: Patients with malignancy, Congenital deformities of urogenital tract or any pathology other than BPH. Patients with high Diabetes Mellitus Hypertension systolic 140 mm Hg or higher diastolic 90 mm Hg or higher, Renal disorders or any other systemic disease. Patients planned for surgical treatment of BPH. Urinary bladder calculus. History of chronic prostatic diseases. Patients with disturbed low BPH associated QoL scores. Allergy or sensitivity to pumpkin seed oil.

Design outcomes

Primary

MeasureTime frame
To improve IPSS in patients of BPHTimepoint: Visit 1 Screening Visit Day 0 Visit 2 Month 1 Week 4 Visit 3 Month 2 Week 8 Visit 4 Month 3 Week 12

Secondary

MeasureTime frame
To asses the change in the PSA levelTimepoint: Baseline and Month 3 (Week 12);To asses the change in the QOLTimepoint: Baseline and Month 3 (WEEK 12);To assess the adverse events and vital signsTimepoint: Baseline, Month 1 (Week 4), Month 2 (Week 8) and Month 3 (Week 12)

Countries

India

Contacts

Public ContactMr Sunil Gupta

Pharexcelconsulting private Limited

info@pharexcelconsulting.com09878551428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026